Moberg Pharma's products are based on innovative drug delivery of proven compounds – a strategy which reduces time to market, development cost and risk. Moberg Pharma’s product families includes
Emtrix® for damaged nails (Nalox™ in Sweden),
Kerasal® for podiatric treatments,
JointFlex® for topical treatment of pain and
Kaprolac® for treatment of dandruff-related problems. The company is working on several additional pharmaceutical projects, including nail fungus (onychomycosis). In addition to internal inventions, the portfolio includes acquired and in-licensed products and projects.
To visit our U.S. company website,
please click here.